October 8, 2013HypertensionOpen Access

Signal Regulatory Protein-α Protects Against Cardiac Hypertrophy Via the Disruption of Toll-Like Receptor 4 Signaling

View Full Paper

Ask AI

Bookmark

Why the study?

Does SIRPA protect against pathological cardiac hypertrophy in response to pressure overload?

Structured PICO

Does SIRPA protect against pathological cardiac hypertrophy in response to pressure overload?

Population

SIRPA knockout mice, transgenic mice with cardiac-specific SIRPA overexpression, human dilated cardiomyopathy heart samples, and in vitro cardiomyocytes

Intervention

Aortic banding surgery (pressure overload) or angiotensin II treatment

Comparator

SIRPA(+/+) (wild-type) mice

Outcome

Cardiac hypertrophy, cardiac fibrosis, and contractile functionsurrogate

SIRPA protects against pathological cardiac hypertrophy and remodeling by negatively regulating the Toll-like receptor 4/nuclear factor-κB signaling pathway.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Hypothesis-generating for SIRPA in pressure-overload hypertrophy; human studies needed before clinical translation.

Cite This Study

Jiang et al. (2013) studied this question.

synapsesocial.com/papers/6a7efd73a11f4f846b8ed071 https://doi.org/10.1161/hypertensionaha.113.01506

View Full Paper

Ask AI

Bookmark

Signal Regulatory Protein-α Protects Against Cardiac Hypertrophy Via the Disruption of Toll-Like Receptor 4 Signaling

Structured PICO

Discussion

Implication

Cite This Study

Signal Regulatory Protein-α Protects Against Cardiac Hypertrophy Via the Disruption of Toll-Like Receptor 4 Signaling

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider